Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

NCT00102297 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT00102297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus
Lead sponsor
Kyntra Bio
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2005
Completion date
June 30, 2007
Enrollment
20 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus